3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Melanoma
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Recurrent Squamous Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
Liver Neoplasms
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Solid Tumor
1
Sarcoma, Synovial
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
tremelimumab
×
Clear all
NCT01843374
2026-03-05
Tremelimumab
MedImmune LLC
Phase 2
Active not recruiting
571 enrolled
19 charts